Items where Author is "Wymann, M."
Number of items: 6. 2023Fischer, F. B. and Bigler, M. and Mäusezahl, D. and Hattendorf, J. and Egli, A. and Julian, T. R. and Rölli, F. and Gaia, V. and Wymann, M. and Fridez, F. and Bertschi, S.. (2023) Legionnaires' disease in Switzerland: rationale and study protocol of a prospective national case-control and molecular source attribution study (SwissLEGIO). Infection, 51 (5). pp. 1467-1479. 2017Solinas, G. and Breasson, L. and Becattini, B. and Sardi, C. and Molinaro, A. and Marone, R. and Botindari, F. and Bousquenaud, M. and Ruegg, C. and Wymann, M.. (2017) The role of PI3K gamma signaling within leukocytes in obesity-driven inflammation and insulin resistance. European Journal of Clinical Investigation, 47 (Supplement 1). p. 47. 2016Lupieri, A. and Smirnova, N. F. and Malet, N. F. and Arnal, J. F. and Martinez, L. O. and Wymann, M. and Hirsch, E. and Gayral, S. and Laffargue, M.. (2016) Absence of PI3Kg leads to increased reendothelialization in mice through modulation of IP-10 secretion. Cardiovascular Research, 111 (Supplement 1). S44. 2015Botindari, F. and Wymann, M.. (2015) Dual targeting of PI3K gamma and SHIP1 for a synergistic inhibition of IgE mediated mast cell activation. The FEBS Journal, 282 (1). p. 40. Ettlin, R. and Dieterle, W. and Fabbro, D. and Hebeisen, P. and Beaufils, F. and Hillmann, P. and Stumm, M. and Dimitrijevic, S. and Wymann, M. and Cmiljanovic, N. and Giese, B. and Cmiljanovic, V.. (2015) Early preclinical development of PQR309, a novel balanced dual PI3K/mTOR inhibitor for treatment of various cancer types. Toxicology Letters, 238 (2, Supplement). S337-S338. 2013Zotes, T. M. and Arias, C. F. and Fuster, J. J. and Spada, R. and Perez-Yague, S. and Hirsch, E. and Wymann, M. and Carrera, A. C. and Andres, V. and Barber, D. F.. (2013) PI3K p110γ deletion attenuates murine atherosclerosis by reducing macrophage proliferation but not polarization or apoptosis in lesions. PLoS ONE, Vol. 8, H. 8 , e72674. |
